Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · May 27, 2023

Association of SGLT2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer

JACC: CardioOncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JACC: CardioOncology
The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer
JACC CardioOncology 2023 May 09;[EPub Ahead of Print], H Abdel-Qadir, R Carrasco, PC Austin, et al

Further Reading